Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED TO PRESENT AT WDM
CAPITAL 1st GLOBAL LIFE SCIENCES CONFERENCE IN WARSAW
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX:
PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced today that Marc Voigt, its Chief Financial and Business Officer, will present at the 1st Global Life Sciences Conference in Warsaw, Poland.
Mr. Voigt will provide an overview of the Company and its corporate activities and will be available for a Q&A session following the presentation.
The Company s presentation is scheduled to begin at 12:20 p.m. Central European Time on Monday, September 16, 2013 at the Warsaw Stock Exchange,
Prima BioMed is a globally active leader in the development of personalized bio-therapeutic products for cancer. Prima is dedicated to leveraging its
technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell-based product currently in clinical trials for ovarian
cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative breast cancers.
For further information
Ms. Jessica Brown, Prima BioMed Ltd.
(919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
905505-52; amuehlhaus@edicto.de